HanX Biopharmaceuticals presented a report at the American Society of Hematology 2024 Annual Meeting

On December 7, 2024 HanX Biopharmaceuticals reported presented poster presentations at the 2024 American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting , held in San Diego, CA, USA, December 7–10 : " A Phase IB Clinical Trial INVESTIGATING the Safety, Tolerability, and Pharmacokinetics of HX009," and " A Novel BsAb Dual Targeting PD-1xCD47 in Patients with EBV+ Non-Hodgkin Lymphoma (NHL) (Press release, HanX Biopharmaceuticals, DEC 7, 2024, View Source [SID1234655963]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HX009 is a clinical-stage investigational anti-PD-1 and anti-CD47 bifunctional large molecule cancer immunotherapy independently developed by Hans-Eti. Two Phase I single-agent dose-escalation trials in solid tumors and one in lymphoma have been successfully completed in Australia and China. Single-agent data demonstrated favorable safety and tolerability, with single-agent anti-tumor efficacy observed in multiple indications, including lymphoma. Existing data support advancement to Phase II and combination trials. The company is currently conducting multicenter Phase II trials in multiple clinical indications. This poster presentation reported data from the ongoing Phase IB lymphoma program in the EBV+ NHL subgroup. HX009 demonstrated a favorable safety profile at a single dose of 10 mg/kg Q2W . Preliminary efficacy assessment in 14 patients with refractory/relapsed EBV+ NHL showed three partial responses and four sustained-release (SD) outcomes.

Dr. Henry Li, CEO/CSO of Hans Ait , and Dr. Zhang Lei, CMO, attended this year’s annual meeting and said, "We are very pleased to have the opportunity to report the results of this study to everyone at this annual meeting. Currently, there is no unified standard treatment for EBV+NHL. In clinical practice, the treatment of EBV+ and EBV- basically uses similar drugs with poor efficacy. In this clinical trial, we have observed that HX009 monotherapy can cause objective remission, suggesting the therapeutic potential of HX009 in this indication. We look forward to rapidly advancing this clinical trial and providing patients with new treatment options as soon as possible."

EpimAb Biotherapeutics Announces Oral Presentation for EMB-06 (CND106) First-in-human (FIH) Phase I Study in Multiple Myeloma at the American Society of Hematology (ASH) 2024 Annual Meeting

On December 6, 2024 EpimAb Biotherapeutics, a global clinical stage biotechnology company specializing in the development of bispecific antibodies, reported the acceptance of a late-breaking abstract featuring our novel BCMA targeted T cell engager (TCE) EMB-06 (CND106) as an oral presentation at the American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting in San Diego, California to be held between December 7-10, 2024 (Press release, EpimAb Biotherapeutics, DEC 6, 2024, View Source [SID1234654055]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This presentation will highlight the full Phase I clinical results for EMB-06 (CND106), a novel BCMA targeting TCE designed with an optimized efficacy and safety profile, in relapsed or refractory multiple myeloma patients. EpimAb recently granted the exclusive rights to develop and commercialize EMB-06 (CND106) outside of Greater China to Candid Therapeutics. The oral presentation details are as follows:

Title: A Phase I Study of a Novel BCMA×CD3 Bispecific Antibody EMB-06 in Relapsed or Refractory Multiple Myeloma
Session Date: December 8
Session Time: 10:45 – 11:00AM local time
Location: Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)
Presentation number: 498

"We are very pleased to share the full results of the EMB-06 FIH study as an oral presentation at the ASH (Free ASH Whitepaper) Annual Conference, and we believe the data highlights EMB-06’s differentiated efficacy and safety profile in multiple myeloma patients," said Dr. Chengbin Wu, Founder and CEO of EpimAb. "The results of this study also provide validation of our TCE technology platform and we will further leverage this expertise to advance novel therapies for diseases with significant unmet need."

About EMB-06

EMB-06 is a novel 2+2 BCMA×CD3 T-cell engaging bispecific antibody discovered using EpimAb’s proprietary CD3 panel and bispecific platforms. Importantly, this molecule has demonstrated lower levels of cytokine release in preclinical and clinical studies.

Alpha Tau to Participate in Ladenburg’s Oncology Innovators & Investors Symposium

On December 6, 2024 Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, reported that CFO Raphi Levy will present at the Ladenburg Oncology Innovators & Investors Symposium (Press release, Alpha Tau Medical, DEC 6, 2024, View Source [SID1234648851]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: Ladenburg Oncology Innovators & Investors Symposium
Format: Presentation and 1-on-1 Meetings
Date: December 12, 2024
Time: 11:00AM – 11:25AM EST
Location: Virtual

Please reach out to your Ladenburg representative to schedule 1-on-1 meetings with Mr. Levy.

Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia

On December 6, 2024 Biomea Fusion, Inc. ("Biomea") (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, reported that it will host a conference call and webcast on Monday, December 9, 2024 at 4:30 pm EST to present data from COVALENT-103, the company’s Phase I trial of BMF-500, an investigational covalent FLT3 inhibitor developed using the proprietary FUSION System, in adult patients with relapsed or refractory acute leukemia (Press release, Biomea Fusion, DEC 6, 2024, https://investors.biomeafusion.com/news-releases/news-release-details/biomea-fusion-host-conference-call-present-initial-clinical-data [SID1234648852]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call and Webcast Details
Webcast of Biomea’s investor update on Monday, December 9, 2024 at 4:30 pm EST will be available to registered attendees under the Investors and Media section of the company’s website at View Source A replay of the presentation will be archived on Biomea’s site following the event.

About COVALENT-103
COVALENT-103 is a multicenter, open-label, non-randomized trial seeking to evaluate the safety and efficacy of BMF-500, a twice daily oral treatment, in adult patients with relapsed or refractory acute leukemia with FMS-like tyrosine kinase 3 (FLT3) wild-type and FLT3 mutations. Additional information about the Phase I clinical trial of BMF-500 can be found at ClinicalTrials.gov using the identifier, NCT05918692.

About BMF-500
BMF-500, an investigational, novel, orally bioavailable, highly potent and selective covalent small molecule inhibitor of FLT3, was discovered and developed in-house at Biomea using the company’s proprietary FUSION System and has demonstrated encouraging potential based on extensive preclinical studies. The kinase inhibitory profile of BMF-500 showed high target selectivity, suggesting the potential for reduced off-target liabilities. BMF-500 was designed to have a therapeutic profile to allow for combinations with standard of care and/or novel targeted agents like icovamenib, Biomea’s investigational covalent menin inhibitor currently in clinical development for solid and liquid tumors as well as diabetes.

Previous data presented at the 2022 American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting showed BMF-500’s picomolar affinity for inhibition of activating FLT3 mutations, including FLT3-ITD and various tyrosine kinase domain (TKD) mutations. BMF-500 demonstrated multi-fold higher potency and increased cytotoxicity than the commercially available non-covalent FLT3 inhibitor gilteritinib. These data also showed complete tumor regression in mouse models of FLT3-ITD acute myeloid leukemia (AML), with no tumor regrowth even after treatment cessation.

Data presented at the 2023 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting exhibited the potential utility of combination strategies to achieve higher antileukemic cell killing with reduced concentrations of BMF-500 and icovamenib. Additionally, Biomea has shown the potential of combinatorial approaches of BMF-500 and icovamenib with MEK and BCL2 blockade in other preclinical studies. These data provide preclinical evidence for combining pathway-specific inhibitors as a promising therapeutic strategy for further investigation in acute leukemia.

About FLT3 in AML
FLT3 is a receptor tyrosine kinase (RTK) that plays a central role in the survival, proliferation, and differentiation of immature blood cells. FLT3 gene mutations are common in patients with AML and are associated with a poor prognosis. Nearly 30% of AML patients have a FLT3 mutation, representing more than 7,000 incident patients in the U.S. each year. In addition, academic literature suggests that more than 50% of AML patients with an NPM1 mutation also harbor a FLT3 mutation. While FLT3-specific and pan-tyrosine kinase inhibitors are approved by the FDA across various lines of therapy in AML, these agents have produced relatively low rates of durable responses and overall survival remains an unmet need.

Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) announce up to $7.9m investment from IFLI to support IPH6501 development in Follicular Lymphoma

On December 6, 2024 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), together with the Institute for Follicular Lymphoma (IFLI) reported that they have entered into an agreement to clinically study the potential of IPH6501, Innate’s anti-CD20 ANKET in follicular lymphoma (FL) (Press release, Innate Pharma, DEC 6, 2024, View Source [SID1234648853]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Innate’s ongoing Phase 1/2, open-label, multicenter trial investigating the safety, tolerability, and preliminary antineoplastic activity of IPH6501 in patients with relapsed and/or refractory CD20-expressing Non-Hodgkin Lymphoma will also include patients with relapsed / refractory (R/R) FL.

To support the Phase 1/2 trial and inclusion of FL patients, IFLI will initially invest 3m USD into new shares of Innate, issued through a capital increase reserved to IFLI at a price of €1.56 per share and representing 2.26% of the share capital of Innate.

IFLI may also invest up to an additional 4.9m USD into new shares of Innate, depending on the completion of certain milestones, at a price to be determined at the time of the said investments.

"At Innate Pharma, we are deeply committed to advancing innovative research and development to improve outcomes for patients with non-Hodgkin lymphoma and this agreement with the Institute for Follicular Lymphoma Innovation will contribute to our mission to bring forward therapeutic options that address critical needs and enhance the quality of life for those affected by this challenging disease," said Dr Sonia Quaratino, Chief Medical Officer of Innate Pharma.

"IFLI believes IPH6501 holds great promise for improving patient outcomes in non-Hodgkin lymphomas including follicular lymphoma," said Dr Michel Azoulay, Chief Medical Officer of IFLI. "We are delighted to support Innate and the investigation of IPH6501 in FL patients and, upon milestone achievement, to continue to support future clinical development of IPH6501 in FL. This collaboration provides a model for how IFLI’s philanthropic investments can catalyze FL development."